N4 Pharma (N4P)
N4 Pharma and Silicon Valley-based SRI International (‘SRI’) have entered a research collaboration agreement (‘the Agreement’) designed to progress development of preclinical products capable of overcoming barriers that prevent intracellular delivery of large molecule biotherapeutics. SRI is a high reputation not-for-profit scientific research institute, that was originally founded by the trustees of Stanford University in 1946 and today comprises c.1500 professional staff. Its Biosciences division has supported the advancement of >200 drugs to clinical trials. Providing significant validation for Nuvec®, N4P’s unique novel silica nanoparticle delivery technology, the Agreement will utilise SRI’s proprietary FOX Three Molecular Guidance system™ (‘MGS’) platform with a view to advancing development of N4P’s nucleic acid-based therapies. Should combination of the two technologies in due course open new commercial potential, N4P and SRI will work together to identify, develop and pursue related business opportunities.
Read or download the full report here....